A quick review of a patient's medication list is often the fastest and most reliable way to recognize that they have dementia. Common agents you will see include donepezil (Aricept), rivastigmine (Exelon), galantamine (Razadyne), memantine (Namenda), and newer disease-directed therapies such as donanemab (Kisunla). These drugs are prescribed across different stages of cognitive decline, and spotting them should prompt a change in how you plan and conduct the appointment.
Medication entries for antipsychotics (for example, haloperidol/Haldol) or other psychotropics can also signal a history of agitation or aggression, information that is essential for planning safety and behavioral management during care.
Patients with advanced dementia can become agitated abruptly and without an identifiable trigger. The sensory demands of a dental visit—noise, instrumentation, unfamiliar surroundings—can exacerbate agitation. Practical strategies include scheduling shorter morning visits, avoiding confrontation, speaking quietly, acknowledging the patient's experience, and using de-escalation techniques. If agitation is recurrent or severe, contact the treating physician to discuss as-needed (PRN) medication that might be given before or after a dental appointment.
Be aware that many agents used to manage agitation—such as haloperidol, quetiapine, or brexpiprazole—have cardiovascular effects, including prolongation of the QT interval. These cardiac considerations have direct pharmacologic consequences in dentistry: combining QT-prolonging psychotropics with epinephrine-containing local anesthetics can increase the risk of adverse events. When such medications appear on the chart, coordinate with prescribers and use caution in anesthetic selection.
Patients with mild to moderate Alzheimer’s disease commonly take cholinesterase inhibitors: donepezil, rivastigmine, or galantamine. Those with moderate to severe disease often take memantine in addition. From a dental perspective, these medications are not interchangeable: they have distinct indications and side-effect profiles that affect oral care planning.
A recognized adverse effect of donepezil, galantamine, and memantine is xerostomia. Reduced salivary flow accelerates caries risk and influences preventive strategies. Consider prescribing topical fluoride supplements such as PreviDent and provide caregivers with clear instructions for daily oral hygiene, fluoride application, and monitoring.
Prescribing for older adults with dementia requires heightened caution because age-related reductions in renal and hepatic function change drug pharmacokinetics. The geriatric population is also more vulnerable to respiratory depression and central nervous system side effects.
NSAIDs: Though commonly used after dental procedures, adding a dentist-prescribed NSAID to a regimen that already includes an NSAID can substantially increase the risk of gastrointestinal bleeding. The article recounts a preventable, severe GI bleed after ibuprofen was prescribed on top of an existing COX-2 inhibitor.
Opioids, benzodiazepines, and muscle relaxants: If possible, avoid these classes in dementia patients. When unavoidable, use the lowest effective dose for the shortest reasonable duration.
Drug interactions: Macrolide antibiotics (azithromycin, clarithromycin, erythromycin) can prolong the QT interval and should generally be avoided in patients taking other QT-prolonging medications. Antifungals such as fluconazole, commonly used for oral candidiasis in this population, interact with many drugs elderly patients take and warrant careful review before prescribing.
NSAID plus corticosteroid: Co-prescription significantly increases GI bleeding risk and can affect blood pressure; avoid concurrent use when feasible.
Always review current medications, renal and hepatic status where available, and consult the treating physician when in doubt.
One of the most urgent yet under-discussed issues is that patients with moderate to advanced dementia may not reliably report pain. Language deficits can progress to near-complete loss of verbal ability, and oral pain may present only through behavioral changes: refusal to eat, sudden functional decline, increased agitation, or other unexplained behavioral shifts.
Untreated dental pathology—fractured teeth, draining abscesses, spreading infections—can mimic or exacerbate cognitive and behavioral decline. The source describes documented cases in which apparent Alzheimer’s progression resolved after identification and treatment of oral infection. In patients who cannot verbalize discomfort, an undiagnosed toothache represents a medical emergency that can materially affect overall health and behavior.
Routine inspection for infection, caries, and orofacial pain should be prioritized in these patients. Caregiver interviews, observation of feeding and behavioral patterns, and a low threshold for clinical examination and imaging will help identify treatable causes of decline.
Dementia is increasingly common; current data cited in the source estimate millions of Americans aged 65 and older with clinical Alzheimer’s dementia and project a rising prevalence. These are patients who rely on clinicians and caregivers to recognize and address oral disease that they cannot advocate about themselves.
Dentists should view medication lists as diagnostic clues, anticipate altered pharmacokinetics and interaction risks, prioritize prevention for xerostomia-related caries, and recognize behavioral signs as possible indicators of pain or infection. Coordination with prescribers, shortened and quiet appointments, caregiver education, and a proactive approach to detection and treatment of oral disease are practical steps that fulfill the clinical standard owed to this vulnerable population.
The responsibility extends beyond routine dental care: timely identification and treatment of oral pathology can reduce suffering, prevent systemic complications, and in some cases improve cognition and behavior. These patients cannot reliably advocate for themselves—dental clinicians can and should.